Research
The Ming Hsieh Institute aims to make USC an international leader in translational cancer and other areas with large affected populations by bridging basic science, engineered devices, synthesized molecules and materials, and medicine. The Ming Hsieh Institute supports many multi-disciplinary research teams developing new treatments or diagnostics.2023
July 18, 2023
Investigators: Yingxiao Wang, Sarah Richman, Longwei Liu
July 18, 2023
Investigators: Dechen Lin, Uttam Sinha, Jacob Thomas, Cristina Zavaleta
July 18, 2023
Investigators: Yong Zhang, Evanthia Torres
July 18, 2023
Investigators: Qilong Ying, Peter YingXiao Wang, Chao Zhang
July 18, 2023
Investigators: Jorge Nieva, Assad Oberai, Peter Kuhn, Jeremy Mason
July 18, 2023
Investigators: Heinz-Josef Lenz, Evanthia Roussos Torres, Yong Zhang
July 18, 2023
Investigators: Steve Kay, Vsevolod Katritch, Yong-Mi Kim, Deepa Bhojwani
July 18, 2023
Investigators: Julio A. Camarero, Hienz-Joseph Lenz
July 18, 2023
Investigators: Jacob Thomas, Uttam Sinha, Dechen Lin
2022
February 3, 2023
Investigators: Travis Williams, Andy Chang, Jesse Yen
February 3, 2023
Investigators: Stacey Finley, Evanthia Roussos Torres
February 3, 2023
Investigators: Peter Kuhn, Hooman Djaladat, Jeremy Mason
February 3, 2023
Investigators: Michael Khoo, Thomas Coates, Saranya Veluswamy
February 3, 2023
Investigators: Yan Liu, Joseph Carlson
February 3, 2023
Investigators: Eun Ji Chung, Kenneth Hallows
2021
June 30, 2021
Investigators: Zhaoyang Fan; Krishna Nayak
June 29, 2021
Investigators: Min Yu; Yong Zhang; Irene Kang
June 29, 2021
Investigators: Jianming Xie; Alan Wayne; Yong-Mi Kim
June 29, 2021
Investigators: Yong Zhang; Heinz-Josef Lenz; Alan Epstein
June 29, 2021
Investigators: Cristina Zavaleta; Manju Aron; Uttam Sinha; Scott Fraser
June 29, 2021
Investigators: Justin Haldar; Jay Acharya
June 29, 2021
Investigators: Kimberly Gokoffski; Gianluca Lazzi
June 29, 2021
Investigators: Eun Ji Chung; Mitchell Gross; Russell Jacobs; Alex Wong
2020
August 28, 2020
Investigators: Richard Roberts; Terry Takahashi
August 6, 2020
Investigators: Heinz-Josef Lenz; Fariborz Nasertorabi
August 6, 2020
Investigators: Jianming Xie; Alan Wayne
August 6, 2020
Investigators: Stan Louie; Mark Humayun
August 4, 2020
Investigators: Assad Oberai; Vinay Duddalwar; Inderbir Gill
August 6, 2020
Investigators: Hossein Jadvar; Andrew MacKay; Krishna Nayak;
August 6, 2020
Investigators: Houda Alachkar; Andrew Mackay; George Yaghmour
2019
July 11, 2019
Investigators: Kevin Kelly; Peter Kuhn; Wendy Cozen
July 11, 2019
Investigators: Peter Kuhn; Jorge Nieva
July 11, 2019
Investigators: Mark Humayun; Stan Louie
July 11, 2019
Investigators: Ellis Meng; Gordon McComb
July 11, 2019
Investigators: Preet Chaudhary; Jianming Xie
July 11, 2019
Investigators: Anthony El-Khoueiry; Jacob Thomas; Stan Louie; Alan Epstein
July 11, 2019
Investigators: Alan Epstein; Stan Louie
July 11, 2019
Investigators: Seth John; Peter Kuhn; Jorge Nieva; Josh West; Will Berelson
2018
July 11, 2018
Investigators: Akil Merchant; Kevin Kelly; Wendy Cozen; James Hicks; Peter Kuhn; Imran Siddiqi
July 11, 2018
July 11, 2018
Investigators: Eun Ji Chung; Mitchell Gross; Kian Kani; Keyue Shen
July 11, 2018
Investigators: Preet Chaudhary; Jianming Xie
2017
July 11, 2017
Investigators: Yong Zhang; Heinz-Josef Lenz
June 5, 2017
Investigators: Nicos Petasis Ph.D.; Stan Louie Ph.D.; Heinz-Josef Lenz M.D.
Innovation: developing non-cytotoxic small molecules that cause tumor death through suppression of inflammation
Clinical significance: provides a new treatment for colon cancer and other inflammation-related cancers
Innovation: developing non-cytotoxic small molecules that cause tumor death through suppression of inflammation
Clinical significance: provides a new treatment for colon cancer and other inflammation-related cancers
June 5, 2017
Investigators: Akil Merchant M.D.; Parkash Gill M.D.; Peter Kuhn Ph.D.; Imran Siddiqi MD Ph.D.
Innovation: developing an imaging technique to study immune cells and understand their connection to tumors
Clinical significance: gain insights into immune response for patients being treated with immuno-oncology agents
Innovation: developing an imaging technique to study immune cells and understand their connection to tumors
Clinical significance: gain insights into immune response for patients being treated with immuno-oncology agents
July 21, 2017
Investigators: Yan Liu; Peter Kuhn; James Hicks; Jorge Nieva
June 5, 2017
Investigators: Noah Malmstadt Ph.D.; Robert Seeger M.D. M.S.; Muller Fabbri M.D. Ph.D.; Ambrose Jong Ph. D.; Alan Wayne M.D.
Innovation: develop a new, automated, large-scale device for purifying NK EVs and characterize their ability to kill human ALL and NB cell lines in vitro and cell lines and patient derived xenografts
Clinical significance: new approach to the treatment of cancer that may be effective against a wide array of malignancies in children and adults
Innovation: develop a new, automated, large-scale device for purifying NK EVs and characterize their ability to kill human ALL and NB cell lines in vitro and cell lines and patient derived xenografts
Clinical significance: new approach to the treatment of cancer that may be effective against a wide array of malignancies in children and adults
July 21, 2017
Investigators: Stephen Gruber; Fei Sha
2016
March 2, 2016
Investigators: J. Andrew MacKay, Ph.D. Peter Conti, M.D., Ph.D., Alan Epstein, M.D., Ph.D. Zibo Li, Ph.D.
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients
July 21, 2016
Investigators: Richard Roberts; Mitchell Gross; Terry Takahashi
July 21, 2016
Investigators: Stan Louie; Kathleen Rodgers; Nicos Petasis; Louis Dubeau
2015
July 22, 2015
Investigators: Nicos Petasis; Stan Louie; Heinz-Josef Lenz
July 22, 2015
Investigators: Yong Zhang; Parkash Gill
July 22, 2015
Investigators: Kai Chen; Peter Conti; Kirk Shung
July 22, 2015
Investigators: Kathleen Rodgers; Stan Louie; Gere diZerega
July 21, 2015
Investigators: Stan Louie; Nicos Petasis; Kathleen Rodgers
2014
March 2, 2016
Investigators: J. Andrew MacKay, Ph.D. Peter Conti, M.D., Ph.D., Alan Epstein, M.D., Ph.D. Zibo Li, Ph.D.
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients
March 1, 2014
Investigators: Wei Wu, Ph.D.; Mahta Moghaddam, Ph.D.; John Stang, Ph.D.; Eugene Chung, M.D., Ph.D., J.D.
Innovation: a new class of custom-engineered nanoparticles that enhance absorption at microwave frequencies
Clinical significance: noninvasive, less painful therapy, especially beneficial for patients unable to undergo surgery
Innovation: a new class of custom-engineered nanoparticles that enhance absorption at microwave frequencies
Clinical significance: noninvasive, less painful therapy, especially beneficial for patients unable to undergo surgery
July 22, 2014
Investigators: Mark Thompson; Chongwu Zhou
March 1, 2014
Investigators: Andrea Armani, Ph.D.; Charles Gomer, Ph.D.; David Agus, M.D.; Qifa Zhou, Ph.D.
Innovation: combining nanotechnology with ultrasound waves
Clinical significance: increasing the penetration depth of nanoparticle- enhanced therapy to reach previously inaccessible tumors
Innovation: combining nanotechnology with ultrasound waves
Clinical significance: increasing the penetration depth of nanoparticle- enhanced therapy to reach previously inaccessible tumors
March 2, 2014
Investigators:Min Yu, M.D., Ph.D. Pin Wang, Ph.D., Julie Lang, M.D.
Innovation: delivering a novel nanoparticle/TAK1 inhibitor to halt metastasis
Clinical significance: a new treatment for metastatic breast cancer
Innovation: delivering a novel nanoparticle/TAK1 inhibitor to halt metastasis
Clinical significance: a new treatment for metastatic breast cancer
March 2, 2014
Investigators: Jennica Zaro, Ph.D. Peter Conti, M.D., Ph.D.
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects
2013
March 1, 2013
Investigators: Richard Roberts, Ph.D.; Uttam Sinha, M.D.
Innovation: develop high-affinity peptides for targeted diagnosis and a pipeline for generating other reagents
Clinical significance: a robust, simple diagnostic test for early detection of head and neck cancers
Innovation: develop high-affinity peptides for targeted diagnosis and a pipeline for generating other reagents
Clinical significance: a robust, simple diagnostic test for early detection of head and neck cancers
March 1, 2013
Investigators: J. Andrew MacKay, Ph.D.; Peter Conti, M.D., Ph.D.
Innovation: developing a timepoint-independent pharmacokinetic modeling strategy
Clinical significance: improving personalized medicine by more accurately measuring the effects of a particular treatment on an individual patient
Innovation: developing a timepoint-independent pharmacokinetic modeling strategy
Clinical significance: improving personalized medicine by more accurately measuring the effects of a particular treatment on an individual patient
February 27, 2013
Investigators: Fabien Pinaud, Ph.D.; Mitchell Gross, M.D., Ph.D.; Charles McKenna, Ph.D.
Innovation: combining drugs that prevent bone loss with gold nanoparticles to treat metastatic bone cancer
Clinical significance: enhancing the chance of survival for patients with few current options
Innovation: combining drugs that prevent bone loss with gold nanoparticles to treat metastatic bone cancer
Clinical significance: enhancing the chance of survival for patients with few current options
2012
July 22, 2012
Investigators: Jennica Zaro; Peter Conti
July 22, 2012
Investigators: Timothy Triche; Richard Roberts
July 22, 2012
Investigators: Stephen Bradforth; Colin Hill; Jay Nadeau; Jonathon Ha; Eric Chang
March 2, 2014
Investigators: Jennica Zaro, Ph.D. Peter Conti, M.D., Ph.D.
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects
July 22, 2012
Investigators: Chongwu Zhou; Mark Thompson; Thomas Chen
2011
July 22, 2011
Investigators: Amir Goldkorn; Nicos Petasis
July 22, 2011
Investigators: Pin Wang; Michael Wong
March 1, 2013
Investigators: J. Andrew MacKay, Ph.D.; Peter Conti, M.D., Ph.D.
Innovation: developing a timepoint-independent pharmacokinetic modeling strategy
Clinical significance: improving personalized medicine by more accurately measuring the effects of a particular treatment on an individual patient
Innovation: developing a timepoint-independent pharmacokinetic modeling strategy
Clinical significance: improving personalized medicine by more accurately measuring the effects of a particular treatment on an individual patient
July 22, 2011
Investigators: Travis Williams; Andy Chang